Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
RESEARCH LETTER
Introducing CAR T-cell therapy into clinical practice for mantle cell lymphoma: real-world experience from Poland
1
Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland
Submission date: 2025-10-29
Final revision date: 2025-12-23
Acceptance date: 2026-01-09
Online publication date: 2026-02-12
Corresponding author
Anna Łojko-Dankowska
Department of Hematology and Bone Marrow Transplantation Poznan University of Medical Sciences Poznan, Poland
Department of Hematology and Bone Marrow Transplantation Poznan University of Medical Sciences Poznan, Poland
TOPICS
REFERENCES (17)
1.
Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of Non-Hodgkin’s Lymphoma. Med Sci 2021; 9: 5.
2.
Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol 2016; 34: 1256-69.
3.
Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 2019; 104: e211-4.
4.
Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 2015; 26: 1175-9.
5.
Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016; 127: 1559-63.
6.
Hess G, Dreyling M, Oberic L, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol 2023; 202: 749-59.
7.
Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020; 382: 1331-42.
8.
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625-38.
9.
Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 2023; 142: 865-77.
10.
Rejeski K, Sanz J, Fei T, et al. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood 2025; 146: 834-46.
11.
Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol 2023; 41: 2594-606.
12.
Ahmed N, Thiruvengadam S, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv 2025; 9: 5382-96.
13.
Iacoboni G, Rejeski K, Villacampa G, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2022; 6: 3606-10.
14.
Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 Study. J Clin Oncol 2023; 41: 555-67.
15.
Joseph T, Sanchez J, Abbasi A, et al. Cardiotoxic effects following CAR-T cell therapy: a literature review. Curr Oncol Rep 2025; 27: 135-47.
16.
Goldman A, Maor E, Bomze D, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021; 78: 1800-13.
17.
Shouval R, Goldman A, Flynn JR, et al. Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: incidence, risk factors and biomarker profile. Br J Haematol 2024; 205: 978-89.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
